Download PDF
Endoscopy 2001; 33(1): 8-15
DOI: 10.1055/s-2001-11183
Review
© Georg Thieme Verlag Stuttgart · New York

Ulcer and Gastritis

W. K. Leung 1 , D. Y. Graham 2
  • 1 Dept. of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
  • 2 Digestive Diseases Section, Dept. of Medicine, Baylor College of Medicine and Veterans' Association Medical Center, Houston, Texas, USA
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Recent progress in the area of ulcer and gastritis is still dominated by findings and reports on Helicobacter pylori and nonsteroidal anti-inflammatory drugs, which in turn are the two major causes of peptic ulcers. Although the prevalence of H. pylori is declining in most developed countries, it is still contributing to a significant proportion of peptic ulcers globally. The interrelationship of H. pylori gastritis in patients with gastroesophageal reflux has become more apparent. H. pylori-induced gastric body gastritis is associated with reduced acid production, and thus with reduced reflux and esophagitis. The controversies regarding the interactions between H. pylori and NSAIDs have still not been settled. With the availability of the new COX-2-specific inhibitors, the current scenario of NSAID-related gastroduodenal complications will certainly change. Short-term usage of these agents has significantly reduced the incidence of endoscopic ulcers, but the benefits in terms of clinical outcomes, such as bleeding or perforation, remain to be determined. This review summarizes the recent literature on peptic ulcer and gastritis.

References

  • 1 Vaira D, Malfertheiner P, Megraud F, et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European Study Group.  Lancet. 1999;  354 30-33
    CrossrefPubMedGoogle Scholar
  • 2 Graham D Y. Therapy of Helicobacter pylori: current status and issues.  Gastroenterology. 2000;  118 S2-S8
    CrossrefPubMedGoogle Scholar
  • 3 Gisbert J P, Gisbert J L, Marcos S, et al. Seven-day “rescue” therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.  Aliment Pharmacol Ther. 1999;  13 1311-1316
    CrossrefPubMedGoogle Scholar
  • 4 Rinaldi V, Zullo A, de Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy.  Aliment Pharmacol Ther. 1999;  13 163-168
    CrossrefPubMedGoogle Scholar
  • 5 Lee J M, Breslin N P, Hyde D K, et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.  Aliment Pharmacol Ther. 1999;  13 489-496
    CrossrefPubMedGoogle Scholar
  • 6 Perri F, Festa V, Clemente R, et al. Rifabutin-based “rescue therapy” for Helicobacter pylori infected patients after failure of standard regimens.  Aliment Pharmacol Ther. 2000;  14 311-316
    CrossrefPubMedGoogle Scholar
  • 7 Chan F K, Sung J J, Suen R, et al. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies.  Aliment Pharmacol Ther. 2000;  14 91-95
    CrossrefPubMedGoogle Scholar
  • 8 Yamaoka Y, Kodama T, Gutierrez O, et al. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries.  J Clin Microbiol. 1999;  37 2274-2279
    PubMedGoogle Scholar
  • 9 Yamaoka Y, Kodama T, Kita M, et al. Relation between clinical presentation, Helicobacter pylori density, interleukin-1β and 8 production, and cagA status.  Gut. 1999;  45 804-811
    CrossrefPubMedGoogle Scholar
  • 10 Graham D Y, Osato M S. H. pylori in the pathogenesis of duodenal ulcer: interaction between duodenal acid load, bile, and H. pylori.  Am J Gastroenterol. 2000;  95 87-91
    CrossrefPubMedGoogle Scholar
  • 11 Bodger K, Eastwood P G, Manning S I, et al. Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia guidelines (1996).  Aliment Pharmacol Ther. 2000;  14 413-420
    CrossrefPubMedGoogle Scholar
  • 12 Blum A L, Talley N J, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia: omeprazole plus clarithromycin and amoxicillin effect one year after treatment (OCAY) study group.  N Engl J Med. 1998;  339 1875-1881
    CrossrefPubMedGoogle Scholar
  • 13 Talley N J, Vakil N, Ballard ED I I, Fennerty M B. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia.  N Engl J Med. 1999;  341 1106-1111
    CrossrefPubMedGoogle Scholar
  • 14 McColl K, Murray L, el-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.  N Engl J Med. 1998;  339 1869-1874
    CrossrefPubMedGoogle Scholar
  • 15 Jaakkimainen R L, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis.  Br Med J. 1999;  319 1040-1044
    PubMedGoogle Scholar
  • 16 Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients: a double-blind placebo-controlled study.  Aliment Pharmacol Ther. 2000;  14 317-324
    CrossrefPubMedGoogle Scholar
  • 17 Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.  Lancet. 2000;  355 1665-1669
    CrossrefPubMedGoogle Scholar
  • 18 Moayyedi P, Forman D, Braunholtz D, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group.  Am J Gastroenterol. 2000;  95 1448-1455
    PubMedGoogle Scholar
  • 19 Sobala G M, Crabtree J E, Pentith J A, et al. Screening dyspepsia by serology to Helicobacter pylori.  Lancet. 1991;  338 94-96
    CrossrefPubMedGoogle Scholar
  • 20 Heaney A, Collins J S, Watson R G, et al. A prospective randomised trial of a “test and treat” policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic.  Gut. 1999;  45 186-190
    PubMedGoogle Scholar
  • 21 Lassen A T, Pedersen F M, Bytzer P, et al. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial.  Lancet. 2000;  356 455-460
    CrossrefPubMedGoogle Scholar
  • 22 Graham D Y. Can therapy ever be denied for Helicobacter pylori infection?.  Gastroenterology. 1997;  113 S113-117
    PubMedGoogle Scholar
  • 23 Ciociola A A, McSorley D J, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated.  Am J Gastroenterol. 1999;  94 1834-1840
    CrossrefPubMedGoogle Scholar
  • 24 Lee J M, Breslin N P, Fallon C, O'Morain C A. Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding.  Am J Gastroenterol. 2000;  95 1166-1170
    CrossrefPubMedGoogle Scholar
  • 25 Tu T C, Lee C L, Wu C H, et al. Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers.  Gastrointest Endosc. 1999;  49 302-306
    PubMedGoogle Scholar
  • 26 Graham D Y, Genta R, Evans D G, et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole.  Am J Gastroenterol. 1996;  91 2120-2124
    PubMedGoogle Scholar
  • 27 Sung J J, Lin S R, Ching J Y, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study.  Gastroenterology. 2000;  119 7-14
    CrossrefPubMedGoogle Scholar
  • 28 Nardone G, Staibano S, Rocco A, et al. Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis.  Gut. 1999;  44 789-799
    PubMedGoogle Scholar
  • 29 El-Zimaity H M, Graham D Y. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System.  Hum Pathol. 1999;  3 72-77
    PubMedGoogle Scholar
  • 30 Kuipers E J, Lundell L, Klinkenberg-Knol E C, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.  N Engl J Med. 1996;  334 1018-1022
    CrossrefPubMedGoogle Scholar
  • 31 Klinkenberg-Knol E C, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.  Gastroenterology. 2000;  118 661-669
    PubMedGoogle Scholar
  • 32 Schenk B E, Kuipers E J, Nelis G F, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.  Gut. 2000;  46 615-621
    CrossrefPubMedGoogle Scholar
  • 33 Lamberts R, Creutzfeldt W, Struber H G, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.  Gastroenterology. 1993;  104 1356-1370
    PubMedGoogle Scholar
  • 34 Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.  Aliment Pharmacol Ther. 1998;  12 735-740
    CrossrefPubMedGoogle Scholar
  • 35 Stolte M, Bethke B. Elimination of Helicobacter pylori under treatment with omeprazole.  Z Gastroenterol. 1990;  28 271-274
    PubMedGoogle Scholar
  • 36 Klinkenberg-Knol E C, Festen H P, Jansen J B, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.  Ann Intern Med. 1994;  121 161-167
    PubMedGoogle Scholar
  • 37 Meining A, Bosseckert H, Caspary W F, et al. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients.  Aliment Pharmacol Ther. 1997;  11 729-734
    CrossrefPubMedGoogle Scholar
  • 38 El-Serag H B, Sonnenberg A, Jamal M M, et al. Corpus gastritis is protective against reflux oesophagitis.  Gut. 1999;  45 181-185
    PubMedGoogle Scholar
  • 39 Wu J C, Sung J J, Chan F K, et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease.  Aliment Pharmacol Ther. 2000;  14 427-432
    CrossrefPubMedGoogle Scholar
  • 40 Anand B S, Graham D Y. Ulcer and gastritis.  Endoscopy. 1999;  31 215-225
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Aalykke C, Lauritsen J M, Hallas J, et al. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study.  Gastroenterology. 1999;  116 1305-1309
    PubMedGoogle Scholar
  • 42 Santolaria S, Lanas A, Benito R, et al. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users.  Aliment Pharmacol Ther. 1999;  13 1511-1518
    CrossrefPubMedGoogle Scholar
  • 43 Ng T M, Fock K M, Khor J L, et al. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer.  Aliment Pharmacol Ther. 2000;  14 203-209
    CrossrefPubMedGoogle Scholar
  • 44 Weil J, Langman M J, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.  Gut. 2000;  46 27-31
    CrossrefPubMedGoogle Scholar
  • 45 Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans.  Gastroenterology. 1999;  117 17-25
    PubMedGoogle Scholar
  • 46 Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition.  Circulation. 1985;  72 1177-1784
    PubMedGoogle Scholar
  • 47 Dutch TIA Trial Study G roup. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.  N Engl J Med. 1991;  325 1261-1266
    PubMedGoogle Scholar
  • 48 Kallmann R, Nieuwenhuis H K, de Groot P G, et al. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects.  Thromb Res. 1987;  45 355-361
    CrossrefPubMedGoogle Scholar
  • 49 Hoffmann W, Nitschke M, Muche J, et al. Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study.  Prostaglandins Leukot Essent Fatty Acids. 1991;  42 137-139
    CrossrefPubMedGoogle Scholar
  • 50 Hoffman W, Forster W. Two year Cottbus reinfarction study with 30 mg aspirin per day.  Prostaglandins Leukot Essent Fatty Acids. 1991;  44 159-169
    CrossrefPubMedGoogle Scholar
  • 51 Muller P, Dammann H G, Marinis E, Simon B. Gastrointestinal tolerance of 30 mg versus 300 mg acetylsalicylic acid daily: an endoscopically controlled double-blind study of healthy subjects.  Med Klin. 1990;  85 429-431
    PubMedGoogle Scholar
  • 52 Graham D Y, Moon N. Low-dose aspirin may or may not damage the gastric mucosa [letter].  Gastroenterology. 1999;  117 1505
    PubMedGoogle Scholar
  • 53 Simon L S, Weaver A L, Graham D Y, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.  JAMA. 1999;  282 1921-1928
    CrossrefPubMedGoogle Scholar
  • 54 Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.  Gastroenterology. 1999;  117 776-783
    PubMedGoogle Scholar
  • 55 Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.  Arthritis Rheum. 2000;  43 370-377
    CrossrefPubMedGoogle Scholar
  • 56 Langman M J, Jensen D M, Watson D J, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.  JAMA. 1999;  282 1929-1933
    CrossrefPubMedGoogle Scholar

D. Y. Graham

Digestive Diseases Section, Rm 3A-320
Medical Center (111D)

2002 Holcombe Blvd
Houston, TX 77 030
USA


Fax: Fax:+ 1-713-790-1040

Email: E-mail:dgraham@bcm.tmc.edu